Table 1.
Baseline characteristics of all randomised patients
|
Namilumab vs usual care |
Infliximab vs usual care |
||||
|---|---|---|---|---|---|
| Usual care group (n=54) | Namilumab group (n=57) | Usual care group (n=34) | Infliximab group (n=35) | ||
| Sex | |||||
| Female | 17 (31%) | 23 (40%) | 13 (38%) | 16 (46%) | |
| Male | 37 (69%) | 34 (60%) | 21 (62%) | 19 (54%) | |
| Age, years | 62·8 (51·9–70·5) | 56·2 (47·6–63·3) | 64·5 (51·9–71·9) | 55·4 (46·1–70·5) | |
| Ethnicity | |||||
| White | 33 (61%) | 34 (60%) | 23 (68%) | 17 (49%) | |
| Black | 1 (2%) | 1 (2%) | 0 | 2 (6%) | |
| South Asian | 7 (13%) | 8 (14%) | 3 (9%) | 4 (11%) | |
| Other | 11 (20%) | 14 (25%) | 7 (21%) | 9 (26%) | |
| Not known | 2 (4%) | 0 | 1 (3%) | 3 (9%) | |
| Clinical frailty score level 4–8* | 7 (13%) | 4 (7%) | 5 (15%) | 5 (14%) | |
| Any smoking history | 22 (41%) | 15 (26%) | 11 (32%) | 12 (34%) | |
| Body-mass index, kg/m2 | 29·5 (25·4–34·7) | 30·5 (27·1–35·4) | 30·7 (25·2–34·3) | 32·3 (26·9–35·9) | |
| Background respiratory disease† | 13 (24%) | 13 (23%) | 10 (29%) | 8 (23%) | |
| Background diabetes | 22 (41%) | 17 (30%) | 12 (35%) | 11 (31%) | |
| Care location | |||||
| Ward | 33 (61%) | 33 (58%) | 22 (65%) | 22 (63%) | |
| ICU | 21 (39%) | 24 (42%) | 12 (35%) | 13 (37%) | |
| SARS-CoV-2 PCR result | |||||
| Positive | 50 (93%) | 54 (95%) | 30 (88%) | 29 (83%) | |
| Negative | 3 (6%) | 2 (4%) | 3 (9%) | 6 (17%) | |
| Previous COVID-19 treatment at baseline | |||||
| Corticosteroids | 49 (91%) | 53 (93%) | 29 (85%) | 33 (94%) | |
| Remdesivir | 29 (54%) | 32 (56%) | 21 (62%) | 10 (29%) | |
| Antibiotics | 46 (85%) | 48 (84%) | 28 (82%) | 31 (89%) | |
| Time to enrolment, days‡ | 1 (1–3) | 1 (1–2) | 2 (1–3) | 1 (1–2) | |
| CRP concentration, mg/L | 108·0 (60·0–160·0) | 94·6 (55·4–171·0) | 88·0 (48·8–142·0) | 99·0 (46·0–173·0) | |
| Lymphocyte count, 109/L | 0·8 (0·6–1·2) | 0·9 (0·6–1·1) | 0·9 (0·6–1·3) | 0·9 (0·6–1·0) | |
| Neutrophil count, 109/L | 7·2 (5·4–10·0) | 7·5 (5·0–10·1) | 7·2 (5·5–11·0) | 6·8 (4·5–9·5) | |
| Ferritin, μg/L | 750 (490–1685) | 791 (433–1621) | 676 (506–1022) | 642 (435–1114) | |
| D-dimers, ng/mL | 787 (376–1822) | 592 (227–1418) | 739 (414–1184) | 398 (235–805) | |
Data are n (%) or median (IQR). ICU=intensive care unit. CRP=C-reactive protein.
*
Vulnerable, mildly frail, moderately frail, or severely frail.
†
The number of patients that had at least one lung disease comorbidity of chronic obstructive pulmonary disease, asthma, or interstitial lung disease.
‡
Time from date of hospital admission to date of randomisation.